Shanghai Pharmaceuticals' biopharma M&A fund completes registration

Shanghai Pharmaceuticals Holding (SSE:601607) announced the completion of the private investment fund registration for the Shanghai Biopharmaceutical M&A Fund, in which it is participating as a limited partner with a commitment of CNY 1 billion. The fund, with a total committed capital of CNY 4.66 billion, includes 14 partners, with Shanghai Guotou Pioneer Biomedical Private Equity Fund Partnership (Limited Partnership) holding the largest share at 48.26%. Shanghai Pharmaceuticals' contribution accounts for 21.46% of the total. The fund's manager is Shanghai Real Capital Management Co., Ltd., and the custodian is the Industrial and Commercial Bank of China. The fund was officially registered with the Asset Management Association of China (AMAC).